数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Tony Liu Director, Chief Executive Officer, Chief Financial Officer and Secretary 52 90.03万美元 未持股 2017-03-17
Wen Tao Liu Director 61 8.36万美元 未持股 2017-03-17
Terry A. Belmont Chairman of the Board and Director 71 22.60万美元 未持股 2017-03-17
Nadir Patel Director 46 18.60万美元 未持股 2017-03-17
欧振国 Director 44 18.60万美元 未持股 2017-03-17
Hansheng Zhou Director 53 8.05万美元 未持股 2017-03-17
Gang Ji Director 42 7.60万美元 未持股 2017-03-17

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Tony Liu Director, Chief Executive Officer, Chief Financial Officer and Secretary 52 90.03万美元 未持股 2017-03-17
Andrew Chan Secretary and Senior Vice President 59 55.53万美元 未持股 2017-03-17
Yihong Yao Chief Scientific Officer 49 44.24万美元 未持股 2017-03-17

董事简历

中英对照 |  中文 |  英文
Tony Liu

Tony Liu从2014年1月开始担任该公司的首席财务官兼秘书,从2013年2月到2014年1月,担任该公司的董事。Liu先生从2013年1月开始担任阿里巴巴集团(Alibaba Group)的公司副总裁,处理阿里巴巴的海外投资。从2009年加入阿里巴巴集团以来,Liu先生担任多个职位,包括B2B公司投资、公司融资部的公司副总裁,以及一个全球性电商平台的总经理。从2011年7月到2012年12月,他担任中国万网(HiChina)的首席财务官,该公司是阿里巴巴集团的子公司,阿里巴巴是互联网基础设施服务的提供商。加入阿里巴巴集团前,Liu先生在美国微软公司(Microsoft Corporation)任职19年,他在该公司担任多个财务领导职位。他担任公司战略部的总经理,负责管理微软中国(Microsoft China)的投资战略以及微软的公司战略规划流程。Liu先生在20世纪90年代担任集团会计总监,领导微软的公司融资机构。Liu先生在中国苏州的苏州大学(Suzhou University)获得物理学理学学士学位,并在西雅图太平洋大学(Seattle Pacific University)完成管理信息系统的工商管理硕士学位课程的学习。Liu先生于1992年获得华盛顿州的注册会计师证书。


Tony Liu has served as the Company’s Chief Executive Officer since February 2016 Chief Financial Officer and Secretary since January 2014 and as a Director of the Company since February 2013. Formerly, Mr. Liu served as the Corporate Vice President at Alibaba Group, handling Alibaba’s overseas investments. Since joining Alibaba in 2009 Mr. Liu served in various positions including Corporate Vice President at B2B corporate investment, corporate finance, and General Manager for a global ecommerce platform. From July 2011 to December 2012 he served as CFO for HiChina, a subsidiary of Alibaba, an internet infrastructure service provider. Prior to joining Alibaba, Mr. Liu spent 19 years at Microsoft Corporation where he served a variety of finance leadership roles. He was the General Manager at Corporate Strategy looking after Microsoft China investment strategy and Microsoft corporate strategic planning process. Mr. Liu was a leader in Microsoft corporate finance organization during the 1990s as Corporate Accounting Director. Mr. Liu earned a B.S. degree in Physics from Suzhou University, Suzhou, PRC and has completed MBA/MIS course work at Seattle Pacific University. Mr. Liu obtained his Washington State CPA certificate in 1992.
Tony Liu从2014年1月开始担任该公司的首席财务官兼秘书,从2013年2月到2014年1月,担任该公司的董事。Liu先生从2013年1月开始担任阿里巴巴集团(Alibaba Group)的公司副总裁,处理阿里巴巴的海外投资。从2009年加入阿里巴巴集团以来,Liu先生担任多个职位,包括B2B公司投资、公司融资部的公司副总裁,以及一个全球性电商平台的总经理。从2011年7月到2012年12月,他担任中国万网(HiChina)的首席财务官,该公司是阿里巴巴集团的子公司,阿里巴巴是互联网基础设施服务的提供商。加入阿里巴巴集团前,Liu先生在美国微软公司(Microsoft Corporation)任职19年,他在该公司担任多个财务领导职位。他担任公司战略部的总经理,负责管理微软中国(Microsoft China)的投资战略以及微软的公司战略规划流程。Liu先生在20世纪90年代担任集团会计总监,领导微软的公司融资机构。Liu先生在中国苏州的苏州大学(Suzhou University)获得物理学理学学士学位,并在西雅图太平洋大学(Seattle Pacific University)完成管理信息系统的工商管理硕士学位课程的学习。Liu先生于1992年获得华盛顿州的注册会计师证书。
Tony Liu has served as the Company’s Chief Executive Officer since February 2016 Chief Financial Officer and Secretary since January 2014 and as a Director of the Company since February 2013. Formerly, Mr. Liu served as the Corporate Vice President at Alibaba Group, handling Alibaba’s overseas investments. Since joining Alibaba in 2009 Mr. Liu served in various positions including Corporate Vice President at B2B corporate investment, corporate finance, and General Manager for a global ecommerce platform. From July 2011 to December 2012 he served as CFO for HiChina, a subsidiary of Alibaba, an internet infrastructure service provider. Prior to joining Alibaba, Mr. Liu spent 19 years at Microsoft Corporation where he served a variety of finance leadership roles. He was the General Manager at Corporate Strategy looking after Microsoft China investment strategy and Microsoft corporate strategic planning process. Mr. Liu was a leader in Microsoft corporate finance organization during the 1990s as Corporate Accounting Director. Mr. Liu earned a B.S. degree in Physics from Suzhou University, Suzhou, PRC and has completed MBA/MIS course work at Seattle Pacific University. Mr. Liu obtained his Washington State CPA certificate in 1992.
Wen Tao Liu

Wen Tao Liu从2013年2月开始担任我司首席执行官直到2013年9月29日他随后担任北美地区的总裁,专注于该公司在加拿大和美国的商业战略。从2013年2月开始到现在,他曾经担任过,并将继续担任我司董事会主席。在这之前,Liu博士从2012年3月开始担任我司前身公司——Cellular Biomedicine Group Ltd.的首席执行官。Liu博士领导过大型机构以及创业公司,其拥有为股东提供价值的可靠工作业绩。他拥有在多文化的商业环境下工作的经验,并赢得了客户、同事和行业领袖的尊敬和信任。从2010年7月到2012年2月,Liu博士担任西欧公司(Seeo Inc.)的总裁兼首席执行官,他在该公司领导了一个科学家和创业家组成团队,以使固态锂离子电池在电动汽车和智能网格应用程序得以商业化应用。从2003年到2009年,他担任上海华虹-NEC电子有限公司(Shanghai Huahong NEC Electronics Company)的总裁兼首席执行官。从1989年到2002年,他担任Peregrine Semiconductor的副总裁和总经理,担任美国集成元件技术公司(Integrated Device Technology)的副总裁和总经理,并担任Quality Semiconductor Australia的常务董事。从1984年到1989年,Liu先生担任赛普拉斯半导体公司(Cypress Semiconductor)的多个工程职位。Liu先生在中国南京市的南京大学(Nanjing University)获得化学学士学位。他在纽约州特洛伊市的伦斯莱尔科技学院(Rensselaer Polytechnic Institute)获得化学硕士学位。


Wen Tao Liu Liu has been a director of the Company since October 2013. Dr. Liu has over 30 years of professional career encompassing biomedicine, clean energy and semiconductor industries. He has led multi-national businesses as well as entrepreneurial companies, with a proven track record of delivering financial results and shareholder value. He served on board of directors of various public and private companies in the United States, China, Hong Kong, Canada, and Australia. Dr. Liu previously served as Chairman and CEO of Cellular Biomedicine Group Inc. In October 2013 he transitioned to the role of Executive Chairman of the Board and, in February 2016 to the role of director and strategic advisor to CBMG’s management. Prior to CBMG, Dr. Liu served as President and CEO of Seeo Inc. from July 2010 to Feb 2012 and as director to Aug 2015 where he led a team of scientists and entrepreneurs for the development of solid-state lithium ion battery for electric vehicles and smart grid applications. Under his leadership, Seeo received multiple funding from Department of Energy and venture capital firms. Seeo was elected to Global Cleantech 100 and top Energy Technology Startups in 2011. Before that, Mr. Liu worked 25 years in semiconductor industry. From 2003 to 2009 he was President and CEO of Shanghai Huahong NEC Electronics Company now HHGRACE, for which he received the White Magnolia Award from Shanghai Government for his contribution to international collaboration and economic development of the city. From 1989 to 2002 he was Vice President and GM of Peregrine Semiconductor, Vice President and GM of Integrated Device Technology, Vice President and General Manager of Quality Semiconductor and Managing Director of Quality Semiconductor Australia. Mr. Liu served Cypress Semiconductor in various engineering capacity from 1984 to 1989. Mr. Liu earned a Bachelor’s degree in Chemistry from Nanjing University, Nanjing China. He holds a Doctorate in Physical Chemistry from Rensselaer Polytechnic Institute, Troy New York.
Wen Tao Liu从2013年2月开始担任我司首席执行官直到2013年9月29日他随后担任北美地区的总裁,专注于该公司在加拿大和美国的商业战略。从2013年2月开始到现在,他曾经担任过,并将继续担任我司董事会主席。在这之前,Liu博士从2012年3月开始担任我司前身公司——Cellular Biomedicine Group Ltd.的首席执行官。Liu博士领导过大型机构以及创业公司,其拥有为股东提供价值的可靠工作业绩。他拥有在多文化的商业环境下工作的经验,并赢得了客户、同事和行业领袖的尊敬和信任。从2010年7月到2012年2月,Liu博士担任西欧公司(Seeo Inc.)的总裁兼首席执行官,他在该公司领导了一个科学家和创业家组成团队,以使固态锂离子电池在电动汽车和智能网格应用程序得以商业化应用。从2003年到2009年,他担任上海华虹-NEC电子有限公司(Shanghai Huahong NEC Electronics Company)的总裁兼首席执行官。从1989年到2002年,他担任Peregrine Semiconductor的副总裁和总经理,担任美国集成元件技术公司(Integrated Device Technology)的副总裁和总经理,并担任Quality Semiconductor Australia的常务董事。从1984年到1989年,Liu先生担任赛普拉斯半导体公司(Cypress Semiconductor)的多个工程职位。Liu先生在中国南京市的南京大学(Nanjing University)获得化学学士学位。他在纽约州特洛伊市的伦斯莱尔科技学院(Rensselaer Polytechnic Institute)获得化学硕士学位。
Wen Tao Liu Liu has been a director of the Company since October 2013. Dr. Liu has over 30 years of professional career encompassing biomedicine, clean energy and semiconductor industries. He has led multi-national businesses as well as entrepreneurial companies, with a proven track record of delivering financial results and shareholder value. He served on board of directors of various public and private companies in the United States, China, Hong Kong, Canada, and Australia. Dr. Liu previously served as Chairman and CEO of Cellular Biomedicine Group Inc. In October 2013 he transitioned to the role of Executive Chairman of the Board and, in February 2016 to the role of director and strategic advisor to CBMG’s management. Prior to CBMG, Dr. Liu served as President and CEO of Seeo Inc. from July 2010 to Feb 2012 and as director to Aug 2015 where he led a team of scientists and entrepreneurs for the development of solid-state lithium ion battery for electric vehicles and smart grid applications. Under his leadership, Seeo received multiple funding from Department of Energy and venture capital firms. Seeo was elected to Global Cleantech 100 and top Energy Technology Startups in 2011. Before that, Mr. Liu worked 25 years in semiconductor industry. From 2003 to 2009 he was President and CEO of Shanghai Huahong NEC Electronics Company now HHGRACE, for which he received the White Magnolia Award from Shanghai Government for his contribution to international collaboration and economic development of the city. From 1989 to 2002 he was Vice President and GM of Peregrine Semiconductor, Vice President and GM of Integrated Device Technology, Vice President and General Manager of Quality Semiconductor and Managing Director of Quality Semiconductor Australia. Mr. Liu served Cypress Semiconductor in various engineering capacity from 1984 to 1989. Mr. Liu earned a Bachelor’s degree in Chemistry from Nanjing University, Nanjing China. He holds a Doctorate in Physical Chemistry from Rensselaer Polytechnic Institute, Troy New York.
Terry A. Belmont

Terry A. Belmont拥有超过20年的领导大型学术与非学术医学中心和拥有多校区的医疗保健公司的经验。Belmont先生从2009年开始管理加州大学欧文分校医学中心(UC Irvine Medical Center),其为加州大学欧文健康分校在加利福尼亚州奥兰治县的主要校区,并管理奥兰治、欧文、科斯塔梅萨、阿纳海姆和桑塔阿那风的获审批的门诊机构。从2009年到来后,Belmont领导了几次扩张和革新项目。他协助开设了应用最先进技术的加州大学欧文分校道格拉斯医院(UC Irvine Douglas Hospital),并领导开发了一个以病人为中心的康复花园和一幢7层临床实验室建筑。Belmont先生最近设立了一个在加州大学欧文分校医学中心(UC Irvine Medical Center)进行设施建设的10年期设施总体规划项目,以及在奥兰治县开设诊所的10年期设施总体规划项目。加入加州大学欧文分校医学中心前,从2006年至2009年,Belmont先生担任长堤市纪念医学中心(Long Beach Memorial Medical)与米勒儿童医院(Miller Children’s Hospital)的首席执行官。他还担任几家公司的总裁兼首席执行官,包括St. Joseph Hospital of Orange、太平洋卫生资源(Pacific Health Resources)、加州医院医学中心(California Hospital Medical Center)与HealthForward。Belmont先生参与大量的社区组织,包括奥兰治县世界事务委员会(Orange County World Affairs Council)、南加州眼科学院(Southern California College of Optometry)、美国心脏协会(American Heart Association)与儿童基金会(Children’s Fund)。他担任雷德兰兹大学(University of Redlands)的理事会理事。Belmont先生在加州大学伯克利分校(UC Berkeley)获得主修医院管理的公共卫生硕士学位,并在雷德兰兹大学(University of Redlands)获得商业学士学位。


Terry A. Belmont has been serving CBMG as an Independent Director since December 2013 and as Vice Chairman of the Board from March 2015 to January 2016 when he was elected to serve as Chairman of the Board. He also serves as a member of the Audit Committee and Chair of the Compensation Committee. Since 2009 Mr. Belmont has overseen UC Irvine Medical Center, the main campus of UC Irvine Health, in Orange, Calif., and its licensed ambulatory facilities in Orange, Irvine, Costa Mesa, Anaheim and Santa Ana. Since his arrival in 2009 Mr. Belmont has led several expansion and renovation projects. He helped open the state-of the-art UC Irvine Douglas Hospital and led the development of a patient-centered healing garden and a 7-story clinical laboratory building. Mr. Belmont launched a 10-year facility master planning project for facility development at UC Irvine Medical Center and clinics throughout Orange County. Prior to joining UC Irvine Medical Center, Mr. Belmont served as CEO of Long Beach Memorial Medical Center and Miller Children’s Hospital from 2006-2009. He has also served as president and chief executive officer in several entities, including St. Joseph Hospital of Orange, Pacific Health Resources, California Hospital Medical Center and HealthForward. Mr. Belmont’s substantial community involvement includes board positions with the Orange County World Affairs Council, Southern California College of Optometry, American Heart Association and Children’s Fund. He serves on the Board of Trustees of the University of Redlands. Mr. Belmont received his master’s in public health with a major in hospital administration from UC Berkeley, and a bachelor’s in business from the University of Redlands. In considering Mr. Belmont's eligibility to serve on the Board, the Board considered Mr. Belmont's business acumen in the healthcare industry.
Terry A. Belmont拥有超过20年的领导大型学术与非学术医学中心和拥有多校区的医疗保健公司的经验。Belmont先生从2009年开始管理加州大学欧文分校医学中心(UC Irvine Medical Center),其为加州大学欧文健康分校在加利福尼亚州奥兰治县的主要校区,并管理奥兰治、欧文、科斯塔梅萨、阿纳海姆和桑塔阿那风的获审批的门诊机构。从2009年到来后,Belmont领导了几次扩张和革新项目。他协助开设了应用最先进技术的加州大学欧文分校道格拉斯医院(UC Irvine Douglas Hospital),并领导开发了一个以病人为中心的康复花园和一幢7层临床实验室建筑。Belmont先生最近设立了一个在加州大学欧文分校医学中心(UC Irvine Medical Center)进行设施建设的10年期设施总体规划项目,以及在奥兰治县开设诊所的10年期设施总体规划项目。加入加州大学欧文分校医学中心前,从2006年至2009年,Belmont先生担任长堤市纪念医学中心(Long Beach Memorial Medical)与米勒儿童医院(Miller Children’s Hospital)的首席执行官。他还担任几家公司的总裁兼首席执行官,包括St. Joseph Hospital of Orange、太平洋卫生资源(Pacific Health Resources)、加州医院医学中心(California Hospital Medical Center)与HealthForward。Belmont先生参与大量的社区组织,包括奥兰治县世界事务委员会(Orange County World Affairs Council)、南加州眼科学院(Southern California College of Optometry)、美国心脏协会(American Heart Association)与儿童基金会(Children’s Fund)。他担任雷德兰兹大学(University of Redlands)的理事会理事。Belmont先生在加州大学伯克利分校(UC Berkeley)获得主修医院管理的公共卫生硕士学位,并在雷德兰兹大学(University of Redlands)获得商业学士学位。
Terry A. Belmont has been serving CBMG as an Independent Director since December 2013 and as Vice Chairman of the Board from March 2015 to January 2016 when he was elected to serve as Chairman of the Board. He also serves as a member of the Audit Committee and Chair of the Compensation Committee. Since 2009 Mr. Belmont has overseen UC Irvine Medical Center, the main campus of UC Irvine Health, in Orange, Calif., and its licensed ambulatory facilities in Orange, Irvine, Costa Mesa, Anaheim and Santa Ana. Since his arrival in 2009 Mr. Belmont has led several expansion and renovation projects. He helped open the state-of the-art UC Irvine Douglas Hospital and led the development of a patient-centered healing garden and a 7-story clinical laboratory building. Mr. Belmont launched a 10-year facility master planning project for facility development at UC Irvine Medical Center and clinics throughout Orange County. Prior to joining UC Irvine Medical Center, Mr. Belmont served as CEO of Long Beach Memorial Medical Center and Miller Children’s Hospital from 2006-2009. He has also served as president and chief executive officer in several entities, including St. Joseph Hospital of Orange, Pacific Health Resources, California Hospital Medical Center and HealthForward. Mr. Belmont’s substantial community involvement includes board positions with the Orange County World Affairs Council, Southern California College of Optometry, American Heart Association and Children’s Fund. He serves on the Board of Trustees of the University of Redlands. Mr. Belmont received his master’s in public health with a major in hospital administration from UC Berkeley, and a bachelor’s in business from the University of Redlands. In considering Mr. Belmont's eligibility to serve on the Board, the Board considered Mr. Belmont's business acumen in the healthcare industry.
Nadir Patel

Nadir Patel,Patel先生从2011年7月开始担任公司规划、财务与信息技术部的助理副部长,并担任加拿大的外交部(Canada’s Department of Foreign Affairs)、贸易与发展部(Trade 与 Development)的首席财务官,其工作职责包括战略规划、财务、信息管理与技术、风险管理与绩效。在这之前,从2009年4月到2011年7月,Patel先生担任加拿大驻上海的总领事,致力于提升加拿大与中国的贸易和投资。从2007年夏季到2009年4月,他担任加拿大的外交部( Canada's Department of Foreign Affairs)、贸易与发展部(Trade and Development)的首席谈判代表,代表加拿大政府谈判贸易协议和条款。Patel先生还担任国际发展部研究中心(International Development Research Centre)的理事会理事,并担任其审计并财务委员会委员,以及劳里埃大学(Wilfrid Laurier University)的商业与经济学院的渥太华顾问委员会委员。他在纽约大学(New York University)的斯特恩商学院、伦敦政治经济学院(London School of Economics and Political Science)与巴黎高等商学院(HEC)管理学院获得工商管理硕士学位。


Nadir Patel has served as an independent Director of the Company since July 2014. Mr. Patel is a senior Canadian diplomat currently serving in India. He previously held the position of Chief Financial Officer for Canada’s Department of Foreign Affairs, Trade and Development, which included the responsibilities of strategic planning, corporate finance and operations, risk management and performance. Mr. Patel has previously served as Canada’s Consul General in Shanghai, promoting trade and investment between Canada and China, as well as Canada’s Chief Air Negotiator where he negotiated bilateral treaties on behalf of the Canadian government. Mr. Patel also served on the Board of Governors of the International Development Research Centre and on its Audit and Finance Committee, as well as the Advisory Board of Wilfrid Laurier University’s School of Business and Economics. He has a Master of Business Administration (MBA) from New York University’s Stern School of Business, the London School of Economics and Political Science, and the HEC Paris School of Management.
Nadir Patel,Patel先生从2011年7月开始担任公司规划、财务与信息技术部的助理副部长,并担任加拿大的外交部(Canada’s Department of Foreign Affairs)、贸易与发展部(Trade 与 Development)的首席财务官,其工作职责包括战略规划、财务、信息管理与技术、风险管理与绩效。在这之前,从2009年4月到2011年7月,Patel先生担任加拿大驻上海的总领事,致力于提升加拿大与中国的贸易和投资。从2007年夏季到2009年4月,他担任加拿大的外交部( Canada's Department of Foreign Affairs)、贸易与发展部(Trade and Development)的首席谈判代表,代表加拿大政府谈判贸易协议和条款。Patel先生还担任国际发展部研究中心(International Development Research Centre)的理事会理事,并担任其审计并财务委员会委员,以及劳里埃大学(Wilfrid Laurier University)的商业与经济学院的渥太华顾问委员会委员。他在纽约大学(New York University)的斯特恩商学院、伦敦政治经济学院(London School of Economics and Political Science)与巴黎高等商学院(HEC)管理学院获得工商管理硕士学位。
Nadir Patel has served as an independent Director of the Company since July 2014. Mr. Patel is a senior Canadian diplomat currently serving in India. He previously held the position of Chief Financial Officer for Canada’s Department of Foreign Affairs, Trade and Development, which included the responsibilities of strategic planning, corporate finance and operations, risk management and performance. Mr. Patel has previously served as Canada’s Consul General in Shanghai, promoting trade and investment between Canada and China, as well as Canada’s Chief Air Negotiator where he negotiated bilateral treaties on behalf of the Canadian government. Mr. Patel also served on the Board of Governors of the International Development Research Centre and on its Audit and Finance Committee, as well as the Advisory Board of Wilfrid Laurier University’s School of Business and Economics. He has a Master of Business Administration (MBA) from New York University’s Stern School of Business, the London School of Economics and Political Science, and the HEC Paris School of Management.
欧振国

欧振国,是GT Healthcare Group(私人股本基金,专注于跨境医疗投资)的现任合伙人,以及TUS-Lifetree Capital Partners公司(专注于中国医疗私人股本投资)的合伙人。他也是Simcere Pharmaceutical Group(中国领先的制药公司)的顾问,也是China Nepstar Chain Drugstore Ltd.(NYSE:NPD)的董事会、审计委员会和薪酬委员会的成员。此外,他也担任由香港特别行政区政府创新及科技基金(the Innovation and Technology Fund of the Hong Kong SAR Government)的企业家的支持计划(ESS课程)的上诉委员。从2013年到2015年,他曾担任Ally Bridge Group(跨境生物技术投资基金,专注于从美国到中国的前沿技术)的风险合伙人。他也曾担任Deutsche Bank Group的亚洲医疗投资银行主管,建议该地区医疗上市和并购。此前,他曾担任JAFCO Asia Investment Group的执行董事,负责中国的医疗投资(2008年至2010年),以及Morningside Group的投资董事,负责亚洲的医疗投资(从2000年到2005年)。1995年至1999年,他曾任职KPMG公司、KPMG Corporate Finance Ltd.,负责地区并购交易和金融咨询服务。


Chun Kwok Alan Au,has served as I-Mab director since January 2020. Mr. Au is the founder of GT Healthcare, a private equity fund focusing on cross border healthcare investments, and has served as the managing partner of GT Healthcare since September 2015. Mr. Au has served as a member of the board, and the chairman of the audit committee of CSPC Pharmaceutical Group (HKEX: 1093), a leading pharmaceutical group in China, since January 2021. Mr. Au also has served as a panel member for the Entrepreneur Support Scheme (ESS Program) of the Innovation and Technology Fund of the Hong Kong SAR Government since 2014. Mr. Au was an advisor to Simcere Pharmaceutical Group, a leading pharmaceutical company in China (previously listed on NYSE: SCR, privatized in December 2013, when Mr. Au served as chairman of the special committee on the board of directors). Mr. Au was also a member of the board of China Nepstar Chain Drugstore Ltd. (NYSE: NPD, privatized in September 2016) from March 2013 to August 2016. He was also a member of the board of Cellular BioMedicine Group (Nasdaq: CBMG, privatized in February 2021), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies from November 2014 to February 2021. Prior to these, Mr. Au served as the head of the Asia Healthcare Investment Banking of Deutsche Bank Group, advising healthcare IPOs and M&A in the region from April 2011 to December 2012. Prior to that, Mr. Au served as the executive director at JAFCO Asia Investment Group, responsible for healthcare investments in China from 2008 to 2010. Mr. Au worked at Morningside Group as a director in charge of healthcare investments in Asia from 2000 to 2005. Mr. Au also worked at KPMG and KPMG Corporate Finance from 1995 to 1999. Mr. Au received his bachelor's degree in psychology from Chinese University of Hong Kong in 1995 and his master's degree in management from Columbia Business School in New York in 2007. Mr. Au is a certified public accountant (CPA) in the U.S. and a chartered financial analyst (CFA). He is a member of the Hong Kong Institute of Financial Analysts and member of the American Institute of Certified Public Accountants.
欧振国,是GT Healthcare Group(私人股本基金,专注于跨境医疗投资)的现任合伙人,以及TUS-Lifetree Capital Partners公司(专注于中国医疗私人股本投资)的合伙人。他也是Simcere Pharmaceutical Group(中国领先的制药公司)的顾问,也是China Nepstar Chain Drugstore Ltd.(NYSE:NPD)的董事会、审计委员会和薪酬委员会的成员。此外,他也担任由香港特别行政区政府创新及科技基金(the Innovation and Technology Fund of the Hong Kong SAR Government)的企业家的支持计划(ESS课程)的上诉委员。从2013年到2015年,他曾担任Ally Bridge Group(跨境生物技术投资基金,专注于从美国到中国的前沿技术)的风险合伙人。他也曾担任Deutsche Bank Group的亚洲医疗投资银行主管,建议该地区医疗上市和并购。此前,他曾担任JAFCO Asia Investment Group的执行董事,负责中国的医疗投资(2008年至2010年),以及Morningside Group的投资董事,负责亚洲的医疗投资(从2000年到2005年)。1995年至1999年,他曾任职KPMG公司、KPMG Corporate Finance Ltd.,负责地区并购交易和金融咨询服务。
Chun Kwok Alan Au,has served as I-Mab director since January 2020. Mr. Au is the founder of GT Healthcare, a private equity fund focusing on cross border healthcare investments, and has served as the managing partner of GT Healthcare since September 2015. Mr. Au has served as a member of the board, and the chairman of the audit committee of CSPC Pharmaceutical Group (HKEX: 1093), a leading pharmaceutical group in China, since January 2021. Mr. Au also has served as a panel member for the Entrepreneur Support Scheme (ESS Program) of the Innovation and Technology Fund of the Hong Kong SAR Government since 2014. Mr. Au was an advisor to Simcere Pharmaceutical Group, a leading pharmaceutical company in China (previously listed on NYSE: SCR, privatized in December 2013, when Mr. Au served as chairman of the special committee on the board of directors). Mr. Au was also a member of the board of China Nepstar Chain Drugstore Ltd. (NYSE: NPD, privatized in September 2016) from March 2013 to August 2016. He was also a member of the board of Cellular BioMedicine Group (Nasdaq: CBMG, privatized in February 2021), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies from November 2014 to February 2021. Prior to these, Mr. Au served as the head of the Asia Healthcare Investment Banking of Deutsche Bank Group, advising healthcare IPOs and M&A in the region from April 2011 to December 2012. Prior to that, Mr. Au served as the executive director at JAFCO Asia Investment Group, responsible for healthcare investments in China from 2008 to 2010. Mr. Au worked at Morningside Group as a director in charge of healthcare investments in Asia from 2000 to 2005. Mr. Au also worked at KPMG and KPMG Corporate Finance from 1995 to 1999. Mr. Au received his bachelor's degree in psychology from Chinese University of Hong Kong in 1995 and his master's degree in management from Columbia Business School in New York in 2007. Mr. Au is a certified public accountant (CPA) in the U.S. and a chartered financial analyst (CFA). He is a member of the Hong Kong Institute of Financial Analysts and member of the American Institute of Certified Public Accountants.
Hansheng Zhou

Hansheng Zhou,是一个受人尊敬的经验丰富的高管,拥有超过28年的中国科技产业经验。他目前担任Wuhan Dangdai Science & Technology Industries Group Co., Ltd(Wuhan Dangdai,中国民营企业集团,拥有中国大量医药投资组合)的首席执行官兼主席。他此前曾担任Wuhan Humanwell Healthcare Group Co., Ltd的首席财务官兼董事总经理。他持有Wuhan University的细胞生物学学士学位和动物生物学硕士学位,也获得了Beijing Institute of Technology的应用化学博士学位。


Hansheng Zhou has been a director of the Company since July 2016. He currently serves as Chief Executive Officer and Chairman of Wuhan Dangdai Science & Technology Industries Group Co., Ltd. “Wuhan Dangdai”, a China based privately held conglomerate with a substantial medical and pharmaceutical portfolio in China. Dr. Zhou previously served as Chief Financial Officer and Managing Director of Wuhan Humanwell Healthcare Group Co., Ltd. He holds a bachelor’s degree in Cell Biology and masters in Animal Biology from Wuhan University and has also earned his PhD degree in Applied Chemistry from Beijing Institute of Technology. Dr. Zhou is a member of the Company’s Compensation Committee.
Hansheng Zhou,是一个受人尊敬的经验丰富的高管,拥有超过28年的中国科技产业经验。他目前担任Wuhan Dangdai Science & Technology Industries Group Co., Ltd(Wuhan Dangdai,中国民营企业集团,拥有中国大量医药投资组合)的首席执行官兼主席。他此前曾担任Wuhan Humanwell Healthcare Group Co., Ltd的首席财务官兼董事总经理。他持有Wuhan University的细胞生物学学士学位和动物生物学硕士学位,也获得了Beijing Institute of Technology的应用化学博士学位。
Hansheng Zhou has been a director of the Company since July 2016. He currently serves as Chief Executive Officer and Chairman of Wuhan Dangdai Science & Technology Industries Group Co., Ltd. “Wuhan Dangdai”, a China based privately held conglomerate with a substantial medical and pharmaceutical portfolio in China. Dr. Zhou previously served as Chief Financial Officer and Managing Director of Wuhan Humanwell Healthcare Group Co., Ltd. He holds a bachelor’s degree in Cell Biology and masters in Animal Biology from Wuhan University and has also earned his PhD degree in Applied Chemistry from Beijing Institute of Technology. Dr. Zhou is a member of the Company’s Compensation Committee.
Gang Ji

Gang Ji自2019年以来一直担任我们的董事。Ji先生自2016年以来一直担任Ant Financial的副总裁。他目前是AGTech Holdings Ltd.(在香港联合交易所上市的公司)和Cellular Biomedicine Group的董事。 ,Inc.,在纳斯达克上市的公司。 加入蚂蚁金服之前,他于2008年至2016年担任阿里巴巴集团副总裁。在此之前,季先生曾于2003年至2007年担任Agile Partners副总裁。他曾担任New Margin Ventures的投资合伙人 从2000年至2003年。他于1997年至2000年在毕马威会计师事务所工作。季先生于1997年从对外经济贸易大学获得国际商务管理学士学位。


Gang Ji has served as our director since 2019. Mr. Ji has served as a vice president of Ant Financial since 2016. He is currently a director of AGTech Holdings Ltd., a company listed on the Hong Kong Stock Exchange, and Cellular Biomedicine Group, Inc., a company listed on NASDAQ. Prior to joining Ant Financial, he served as a vice president of Alibaba Group from 2008 to 2016. Prior to that, Mr. Ji served as a vice president of Agile Partners from 2003 to 2007. He worked as an investment associate of New Margin Ventures from 2000 to 2003. He worked at KPMG from 1997 to 2000. Mr. Ji obtained a bachelor’s degree in international business management from University of International Business and Economics in 1997.
Gang Ji自2019年以来一直担任我们的董事。Ji先生自2016年以来一直担任Ant Financial的副总裁。他目前是AGTech Holdings Ltd.(在香港联合交易所上市的公司)和Cellular Biomedicine Group的董事。 ,Inc.,在纳斯达克上市的公司。 加入蚂蚁金服之前,他于2008年至2016年担任阿里巴巴集团副总裁。在此之前,季先生曾于2003年至2007年担任Agile Partners副总裁。他曾担任New Margin Ventures的投资合伙人 从2000年至2003年。他于1997年至2000年在毕马威会计师事务所工作。季先生于1997年从对外经济贸易大学获得国际商务管理学士学位。
Gang Ji has served as our director since 2019. Mr. Ji has served as a vice president of Ant Financial since 2016. He is currently a director of AGTech Holdings Ltd., a company listed on the Hong Kong Stock Exchange, and Cellular Biomedicine Group, Inc., a company listed on NASDAQ. Prior to joining Ant Financial, he served as a vice president of Alibaba Group from 2008 to 2016. Prior to that, Mr. Ji served as a vice president of Agile Partners from 2003 to 2007. He worked as an investment associate of New Margin Ventures from 2000 to 2003. He worked at KPMG from 1997 to 2000. Mr. Ji obtained a bachelor’s degree in international business management from University of International Business and Economics in 1997.

高管简历

中英对照 |  中文 |  英文
Tony Liu

Tony Liu从2014年1月开始担任该公司的首席财务官兼秘书,从2013年2月到2014年1月,担任该公司的董事。Liu先生从2013年1月开始担任阿里巴巴集团(Alibaba Group)的公司副总裁,处理阿里巴巴的海外投资。从2009年加入阿里巴巴集团以来,Liu先生担任多个职位,包括B2B公司投资、公司融资部的公司副总裁,以及一个全球性电商平台的总经理。从2011年7月到2012年12月,他担任中国万网(HiChina)的首席财务官,该公司是阿里巴巴集团的子公司,阿里巴巴是互联网基础设施服务的提供商。加入阿里巴巴集团前,Liu先生在美国微软公司(Microsoft Corporation)任职19年,他在该公司担任多个财务领导职位。他担任公司战略部的总经理,负责管理微软中国(Microsoft China)的投资战略以及微软的公司战略规划流程。Liu先生在20世纪90年代担任集团会计总监,领导微软的公司融资机构。Liu先生在中国苏州的苏州大学(Suzhou University)获得物理学理学学士学位,并在西雅图太平洋大学(Seattle Pacific University)完成管理信息系统的工商管理硕士学位课程的学习。Liu先生于1992年获得华盛顿州的注册会计师证书。


Tony Liu has served as the Company’s Chief Executive Officer since February 2016 Chief Financial Officer and Secretary since January 2014 and as a Director of the Company since February 2013. Formerly, Mr. Liu served as the Corporate Vice President at Alibaba Group, handling Alibaba’s overseas investments. Since joining Alibaba in 2009 Mr. Liu served in various positions including Corporate Vice President at B2B corporate investment, corporate finance, and General Manager for a global ecommerce platform. From July 2011 to December 2012 he served as CFO for HiChina, a subsidiary of Alibaba, an internet infrastructure service provider. Prior to joining Alibaba, Mr. Liu spent 19 years at Microsoft Corporation where he served a variety of finance leadership roles. He was the General Manager at Corporate Strategy looking after Microsoft China investment strategy and Microsoft corporate strategic planning process. Mr. Liu was a leader in Microsoft corporate finance organization during the 1990s as Corporate Accounting Director. Mr. Liu earned a B.S. degree in Physics from Suzhou University, Suzhou, PRC and has completed MBA/MIS course work at Seattle Pacific University. Mr. Liu obtained his Washington State CPA certificate in 1992.
Tony Liu从2014年1月开始担任该公司的首席财务官兼秘书,从2013年2月到2014年1月,担任该公司的董事。Liu先生从2013年1月开始担任阿里巴巴集团(Alibaba Group)的公司副总裁,处理阿里巴巴的海外投资。从2009年加入阿里巴巴集团以来,Liu先生担任多个职位,包括B2B公司投资、公司融资部的公司副总裁,以及一个全球性电商平台的总经理。从2011年7月到2012年12月,他担任中国万网(HiChina)的首席财务官,该公司是阿里巴巴集团的子公司,阿里巴巴是互联网基础设施服务的提供商。加入阿里巴巴集团前,Liu先生在美国微软公司(Microsoft Corporation)任职19年,他在该公司担任多个财务领导职位。他担任公司战略部的总经理,负责管理微软中国(Microsoft China)的投资战略以及微软的公司战略规划流程。Liu先生在20世纪90年代担任集团会计总监,领导微软的公司融资机构。Liu先生在中国苏州的苏州大学(Suzhou University)获得物理学理学学士学位,并在西雅图太平洋大学(Seattle Pacific University)完成管理信息系统的工商管理硕士学位课程的学习。Liu先生于1992年获得华盛顿州的注册会计师证书。
Tony Liu has served as the Company’s Chief Executive Officer since February 2016 Chief Financial Officer and Secretary since January 2014 and as a Director of the Company since February 2013. Formerly, Mr. Liu served as the Corporate Vice President at Alibaba Group, handling Alibaba’s overseas investments. Since joining Alibaba in 2009 Mr. Liu served in various positions including Corporate Vice President at B2B corporate investment, corporate finance, and General Manager for a global ecommerce platform. From July 2011 to December 2012 he served as CFO for HiChina, a subsidiary of Alibaba, an internet infrastructure service provider. Prior to joining Alibaba, Mr. Liu spent 19 years at Microsoft Corporation where he served a variety of finance leadership roles. He was the General Manager at Corporate Strategy looking after Microsoft China investment strategy and Microsoft corporate strategic planning process. Mr. Liu was a leader in Microsoft corporate finance organization during the 1990s as Corporate Accounting Director. Mr. Liu earned a B.S. degree in Physics from Suzhou University, Suzhou, PRC and has completed MBA/MIS course work at Seattle Pacific University. Mr. Liu obtained his Washington State CPA certificate in 1992.
Andrew Chan

Andrew Chan从2014年1月开始担任公司业务开发部的高级副总裁。在这之前,从2011年2月到2014年1月,他担任Cellular Biomedicine Group Ltd.的首席财务官。从2003年到2011年,Chan先生在捷智半导体公司(Jazz Semiconductor)任职,并担任过多个管理职位,专注于业务运营、业务与公司发展。2003年前,Chan先生担任敏迅科技(Mindspeed Technologies)业务运营与供应链管理部的副总裁。Chan先生于2000年担任Conexant Systems的供应链管理部的副总裁。在这之前,Chan先生专注于航空与航天服务行业。他担任美国东方航空公司(Eastern Airlines)、美国大陆捷运(Continental Express)的多个技术与运营管理职位,并在联合信号公司(Allied Signal)——现在该公司叫做霍尼韦尔(Honeywell)担任战略业务开发部的总监。Chan先生在安柏瑞德航空航天大学(Embry Riddle Aeronautical University)获得管理学理学士学位,并在诺瓦大学(Nova University)获得主修计算机系统管理与运营研究的工商管理硕士学位。他还在南德克萨斯法学院(South Texas College of Law)获得法律学博士学位。


Andrew Chan served as Senior Vice President of Corporate Business Development since January 2014 and was appointed Secretary in September 2016. He previously served as Secretary and Chief Financial Officer from February 2011 to January 2014. From 2003 until 2011 Mr. Chan was with Jazz Semiconductor and held various management roles focusing on business operations, business and corporate development. Prior to 2003 Mr. Chan was Vice President of Business Operations and Supply Chain Management for Mindspeed Technologies. In 2000 Mr. Chan served as Vice President of Supply Chain Management at Conexant Systems. Mindspeed and Jazz were spin-offs of Conexant. Previously, Mr. Chan’s focus was in aviation and aerospace services. He served in diverse technical and operations management roles at Eastern Airlines, Continental Express and at Allied Signal now called Honeywell as Sr. Director of Strategic Business Development. Mr. Chan earned a B.S. degree in Management from Embry Riddle Aeronautical University and an MBA with specialization in Computer System Management and Operations Research from Nova University. He also holds a Jurisprudence Doctorate (J.D.) degree from South Texas College of Law.
Andrew Chan从2014年1月开始担任公司业务开发部的高级副总裁。在这之前,从2011年2月到2014年1月,他担任Cellular Biomedicine Group Ltd.的首席财务官。从2003年到2011年,Chan先生在捷智半导体公司(Jazz Semiconductor)任职,并担任过多个管理职位,专注于业务运营、业务与公司发展。2003年前,Chan先生担任敏迅科技(Mindspeed Technologies)业务运营与供应链管理部的副总裁。Chan先生于2000年担任Conexant Systems的供应链管理部的副总裁。在这之前,Chan先生专注于航空与航天服务行业。他担任美国东方航空公司(Eastern Airlines)、美国大陆捷运(Continental Express)的多个技术与运营管理职位,并在联合信号公司(Allied Signal)——现在该公司叫做霍尼韦尔(Honeywell)担任战略业务开发部的总监。Chan先生在安柏瑞德航空航天大学(Embry Riddle Aeronautical University)获得管理学理学士学位,并在诺瓦大学(Nova University)获得主修计算机系统管理与运营研究的工商管理硕士学位。他还在南德克萨斯法学院(South Texas College of Law)获得法律学博士学位。
Andrew Chan served as Senior Vice President of Corporate Business Development since January 2014 and was appointed Secretary in September 2016. He previously served as Secretary and Chief Financial Officer from February 2011 to January 2014. From 2003 until 2011 Mr. Chan was with Jazz Semiconductor and held various management roles focusing on business operations, business and corporate development. Prior to 2003 Mr. Chan was Vice President of Business Operations and Supply Chain Management for Mindspeed Technologies. In 2000 Mr. Chan served as Vice President of Supply Chain Management at Conexant Systems. Mindspeed and Jazz were spin-offs of Conexant. Previously, Mr. Chan’s focus was in aviation and aerospace services. He served in diverse technical and operations management roles at Eastern Airlines, Continental Express and at Allied Signal now called Honeywell as Sr. Director of Strategic Business Development. Mr. Chan earned a B.S. degree in Management from Embry Riddle Aeronautical University and an MBA with specialization in Computer System Management and Operations Research from Nova University. He also holds a Jurisprudence Doctorate (J.D.) degree from South Texas College of Law.
Yihong Yao

Yihong Yao ,2015年8月起担任首席科学官。2005年一直到他担任首席科学官前,在MedImmune担任不同的高级科学职位,包括最近,2011-2015年7月,担任转化科学部门主管和药物基因组学和生物信息学主管。2001-2005年,他在Abbott Bioresearch Center担任转化科学资深科学家。持有上海Fudan University的生物化学学士学位,Boston University的生物信息学硕士学位,以及Kansas University的分子生物学和生物化学博士学位。是Johns Hopkins University医学院的博士后研究员。


Yihong Yao has been Chief Scientific Officer since August 2015. From 2005 until his appointment as Chief Scientific Officer, Mr. Yao served in various senior scientific positions at MedImmune, including most recently as director and head of pharmacogenomics and bioinformatics in the department of Translational Sciences from 2011 to July 2015. From 2001 to 2005 Mr.Yao served as Senior Scientist, Translational Science at Abbott Bioresearch Center. He holds a bachelor’s degree in Biochemistry from Fudan University, Shanghai, China, a master’s degree in Bioinformatics from Boston University, and a PhD in Molecular Biology and Biochemistry from the University of Kansas, and he was a postdoctoral fellow at Johns Hopkins University School of Medicine.
Yihong Yao ,2015年8月起担任首席科学官。2005年一直到他担任首席科学官前,在MedImmune担任不同的高级科学职位,包括最近,2011-2015年7月,担任转化科学部门主管和药物基因组学和生物信息学主管。2001-2005年,他在Abbott Bioresearch Center担任转化科学资深科学家。持有上海Fudan University的生物化学学士学位,Boston University的生物信息学硕士学位,以及Kansas University的分子生物学和生物化学博士学位。是Johns Hopkins University医学院的博士后研究员。
Yihong Yao has been Chief Scientific Officer since August 2015. From 2005 until his appointment as Chief Scientific Officer, Mr. Yao served in various senior scientific positions at MedImmune, including most recently as director and head of pharmacogenomics and bioinformatics in the department of Translational Sciences from 2011 to July 2015. From 2001 to 2005 Mr.Yao served as Senior Scientist, Translational Science at Abbott Bioresearch Center. He holds a bachelor’s degree in Biochemistry from Fudan University, Shanghai, China, a master’s degree in Bioinformatics from Boston University, and a PhD in Molecular Biology and Biochemistry from the University of Kansas, and he was a postdoctoral fellow at Johns Hopkins University School of Medicine.